Minirin (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minirin, is a vasopressin analog presented as a nasal spray for nasal use. It treats central diabetes insipidus, nocturnal enuresis, hemophilia A and von Willebrand disease in appropriate patients.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acetate acts on the antidiuretic hormone pathway and on haemostatic factor regulation. - Central diabetes insipidus: reduces excessive urine output by increasing water reabsorption in the kidneys. - Nocturnal enuresis: decreases nighttime bedwetting episodes through antidiuretic effect. - Hemophilia A: raises plasma factor VIII levels to improve clotting. - von Willebrand disease: increases von Willebrand factor concentration, aiding haemostasis.

Desmopressin nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or congestion. - Headache. - Mild hyponatraemia. - Nausea.

Serious or Rare Side Effects: - Severe hyponatraemia leading to seizures or coma. - Water intoxication with cerebral oedema. - Allergic reactions such as rash or angio‑edema. - Nasal septum perforation. - Hypotension.

Before initiating therapy, consider the following safety measures. - Assess serum sodium: check baseline electrolytes to avoid hyponatraemia. - Monitor fluid intake: advise patients to limit excessive water consumption. - Adjust dose in renal impairment: reduce dose or increase monitoring frequency. - Avoid concomitant antidiuretic agents: drugs that increase ADH effect may raise hyponatraemia risk. - Use caution in elderly patients: increased susceptibility to fluid‑electrolyte disturbances. - Store at room temperature: keep in original container, protect from moisture and light.

Desmopressin can interact with several drug classes.

Major Interactions (Avoid): - Other antidiuretic agents (e.g., chlorpropamide, carbamazepine) – may cause profound hyponatraemia. - MAO inhibitors – increase risk of severe water retention. - NSAIDs – potentiate antidiuretic effect and hyponatraemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics – additive effect on sodium loss. - SSRIs or SNRIs – may enhance hyponatraemia risk. - ACE inhibitors or ARBs – monitor blood pressure and electrolytes. - Oral contraceptives – possible increase in water retention.